Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World StudyD.J. Hughes, Alexandros Georgiou, Benjamin A. Taylor et al.|Cancers|2022Cited by 22
1868P Real-world safety of the 6-weekly pembrolizumab regimen in cancer patients treated in South East LondonMatthaios Kapiris, A. L. Georgiou, L. Cain et al.|Annals of Oncology|2021Cited by 0
Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world dataHelen-Cara Younan, Debra H. Josephs, Shuai Zhang et al.|Lung Cancer|2022Cited by 0